Efficacy of taxane regimens in patients with metastatic angiosarcoma

European Journal of Dermatology

Volumn 21, Issue 4, 2011, Pages 539-545

  Hirata, Taizo ^a   Yonemori, Kan ^a   Ando, Masashi ^a   Hirakawa, Akihiro ^b   Tsuda, Hitoshi ^a   Hasegawa, Tadashi ^c   Chuman, Hirokazu ^a   Namikawa, Kenjiro ^a   Yamazaki, Naoya ^a   Fujiwara, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Sapporo Medical University   (Japan)

Author keywords

Angiosarcoma; Chemotherapy; Metastasis; Prognosis; Taxane

Indexed keywords

ALBUMIN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; PACLITAXEL;

ADOLESCENT; ADULT; AGED; ANGIOSARCOMA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OVERALL SURVIVAL; PATIENT ASSESSMENT; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SOCIAL SUPPORT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOXORUBICIN; FEMALE; HEMANGIOSARCOMA; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS;

EID: 80053038270     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2011.1403     Document Type: Article

References (28)

1. Brennan MF, Lewis JL. Diagnosis and Management of Soft Tissue Sarcoma. London: Martin Dunitz; 2002.
2. Weiss SW, Goldblum JR. Enzingers and Weiss Soft Tissue Tumors. St. Louis, MO: Mosby; 2001.
3. Cha C, Antonescu CR, Quan ML, Maru S, Brennan MF. Long-term results with resection of radiation-induced soft tissue sarcomas. Ann Surg 2004; 239: 903-9.
4. Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphedema. A report of six cases in elephantiasis chirurgica. Cancer 1948; 1: 64-81.
5. Pawlik TM, Paulino AF, McGinn CJ, et al. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer 2003; 98: 1716-26.
6. Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996; 14: 1679-89.
7. Holden CA, Spittle MF, Jones EW. Angiosarcoma of the face and scalp: prognosis and treatment. Cancer 1987; 59: 1046-57.
8. Fodor J, Orosz Z, Szabó E, et al. Angiosarcoma after conservation treatment for breast carcinoma: our experience and a review of the literature. J Am Acad Dermatol 2006; 54: 499-504.
9. Zelek L, Llombart-Cussac A, Terrier P, et al. Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol 2003; 21: 2583-8.
10. Nanus DM, Kelsen D, Clark DG. Radiation-induced angiosarcoma. Cancer 1987; 60: 777-9.
11. Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist 2005; 10: 833-41.
12. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracyclinecontaining first-line regimens-A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 1999; 17: 150-7.
13. Borden EC, Baker LH, Bell RS, et al. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res 2003; 9: 1941-56.
14. Clark MA, Fischer C, Judson I, Thomas JM. Soft tissue sarcomas in adults. N Engl J Med 2005; 353: 701-11.
15. Lahat G, Dhuka AR, Lahat S, et al. Outcome of locally recurrent and metastatic angiosarcoma. Ann Surg Oncol 2009; 16: 2502-9.
16. Schlemmer M, Reichardt P, Verweij J, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2008; 44: 2433-6.
17. Fata F, O'Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999; 86: 2034-7.
18. Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 2005; 104: 361-6.
19. Nagano T, Yamada Y, Ikeda T, Kanki H, Kamo T, Nishigori C. Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients. Cancer 2007; 110: 648-51.
20. Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008; 26: 5269-74.
21. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva, Switzerland: World Health Organization; 1979.
22. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
23. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
24. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995; 332: 1004-14.
25. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996; 2: 1843-9.
26. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997; 57: 81-6.
27. Balcerzak S, Benedetti J, Weiss G, Natale RB. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study. Cancer 1995; 76: 2248-52.
28. Patel S, Linke K, Burgess A, Papadopoulos NE, Plager C, Jenkins J, Benjamin R. Phase II study of paclitaxel in patients with soft tissue sarcomas. Sarcoma 1997; 1: 95-7.